Latest California Healthline Stories
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of the Wall Street Journal, Alice Ollstein of Talking Points Memo and Margot Sanger Katz of The New York Times discuss new health spending numbers from the federal government, as well as how the year-end legislating in Congress is being complicated by health issues.
Dramatic increases in spending that came with the influx of newly insured consumers in 2014 and 2015 appear to be moderating.
Even though congressional Republicans set aside their Obamacare repeal-and-replace efforts this year, here are five major health policy changes that could become law as part of the pending House and Senate proposals.
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post discuss the possible impact of the tax bill on the Medicare program, confirmation hearings for a new secretary of Health and Human Services and the future of the Children’s Health Insurance Program. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
Medicare and insurers struggle to oversee a booming business in testing urine samples. In some cases, pain doctors’ lack of follow-through can turn fatal.
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
Julie Rovner of Kaiser Health News, Sarah Kliff of Vox.com, Joanne Kenen of Politico and Alice Ollstein of Talking Points Memo discuss the inclusion of health policies into the current tax cut debate, including a possible repeal of the fines for people who fail to maintain health insurance.
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.
With the nation’s opioid crisis, urine testing has become a booming business and is especially lucrative for doctors who operate their own labs, a Kaiser Health News investigation finds. And dozens of practitioners have earned ‘the lion’s share’ of their Medicare income exclusively from urine drug screens.